Drugs / PRGN-3005 UltraCAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03907527 | Apr 2019 → Dec 2024 overdue | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Precigen, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRGN-3005 UltraCAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03907527 ↗ |
| Action | Deplete | “engineered in the laboratory to specifically target a protein found on tumor cells and kill them” NCT03907527 ↗ |
| Modality | Cell therapy | “autologous chimeric antigen receptor (CAR) T cells” NCT03907527 ↗ |